10/ 519,654

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | |
|---|---|---|
| NEWS 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS 2 | | "Ask CAS" for self-help around the clock |
| NEWS 3 | DEC 21 | IPC search and display fields enhanced in CA/CAplus with the IPC reform |
| NEWS 4 | DEC 23 | New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2 |
| NEWS 5 | JAN 13 | IPC 8 searching in IFIPAT, IFIUDB, and IFICDB |
| NEWS 6 | JAN 13 | New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC |
| NEWS 7 | JAN 17 | Pre-1988 INPI data added to MARPAT |
| NEWS 8 | JAN 17 | IPC 8 in the WPI family of databases including WPIFV |
| NEWS 9 | JAN 30 | Saved answer limit increased |
| NEWS 10 | JAN 31 | Monthly current-awareness alert (SDI) frequency added to TULSA |
| NEWS 11 | FEB 21 | STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results |
| NEWS 12 | FEB 22 | Status of current WO (PCT) information on STN |
| NEWS 13 | FEB 22 | The IPC thesaurus added to additional patent databases on STN |
| NEWS 14 | FEB 22 | Updates in EPFULL; IPC 8 enhancements added |
| NEWS 15 | FEB 27 | New STN AnaVist pricing effective March 1, 2006 |
| NEWS 16 | FEB 28 | MEDLINE/LMEDLINE reload improves functionality |
| NEWS 17 | FEB 28 | TOXCENTER reloaded with enhancements |
| NEWS 18 | FEB 28 | REGISTRY/ZREGISTRY enhanced with more experimental spectral property data |
| NEWS 19 | MAR 01 | INSPEC reloaded and enhanced |
| NEWS 20 | MAR 03 | Updates in PATDPA; addition of IPC 8 data without attributes |
| NEWS 21 | MAR 08 | X.25 communication option no longer available after June 2006 |

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

```
  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:39:02 ON 16 MAR 2006

=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 18:39:15 ON 16 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   15 MAR 2006  HIGHEST RN 877033-93-7
DICTIONARY FILE UPDATES:  15 MAR 2006  HIGHEST RN 877033-93-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s gleevec or imatinib
             1 GLEEVEC
             2 IMATINIB
L1           2 GLEEVEC OR IMATINIB

=> d scan l1
```

10/ 519,654

L1 2 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI)
MF C29 H31 N7 O
CI COM



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

10/ 519,654

```
=> file hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     9.96      10.17

FILE 'HCAPLUS' ENTERED AT 18:39:39 ON 16 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 16 Mar 2006  VOL 144 ISS 12
FILE LAST UPDATED: 15 Mar 2006  (20060315/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s L1 and (inflammat? or autoimmune or arthritis or lung? or macrophage?)
          1682 L1
        234317 INFLAMMAT?
         44864 AUTOIMMUNE
         40297 ARTHRITIS
        193562 LUNG?
        113183 MACROPHAGE?
L2         279 L1 AND (INFLAMMAT? OR AUTOIMMUNE OR ARTHRITIS OR LUNG? OR MACROP
               HAGE?)

=> s l2 not py>2002
       3637923 PY>2002
L3          19 L2 NOT PY>2002

=> s l3 not leukemia
         95460 LEUKEMIA
L4           6 L3 NOT LEUKEMIA

=> d his

     (FILE 'HOME' ENTERED AT 18:39:02 ON 16 MAR 2006)

     FILE 'REGISTRY' ENTERED AT 18:39:15 ON 16 MAR 2006
L1           2 S GLEEVEC OR IMATINIB

     FILE 'HCAPLUS' ENTERED AT 18:39:39 ON 16 MAR 2006
L2         279 S L1 AND (INFLAMMAT? OR AUTOIMMUNE OR ARTHRITIS OR LUNG? OR MAC
L3          19 S L2 NOT PY>2002
```

10/ 519,654

L4 6 S L3 NOT LEUKEMIA

=> d l4 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 6 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:907361 HCAPLUS
DOCUMENT NUMBER: 139:62329
TITLE: U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid
AUTHOR(S): Cohen, Martin H.; Dagher, Ramzi; Griebel, Donna J.; Ibrahim, Amna; Martin, Alison; Scher, Nancy S.; Sokol, Gerald H.; Williams, Grant A.; Pazdur, Richard
CORPORATE SOURCE: Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD, USA
SOURCE: Oncologist (2002), 7(5), 393-400
CODEN: OCOLF6; ISSN: 1083-7159
PUBLISHER: AlphaMed Press
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review. The purpose of this report is to summarize information on drugs recently approved by the U.S. Food and Drug Administration. Three drugs have recently been approved: Gleevec (imatinib mesylate) at a starting dose off 400 or 600 mg daily for the treatment of malignant unresectable and/or metastatic gastrointestinal stromal tumors; Mesnex (mesna) tablets as a prophylactic agent to reduce the incidence of ifosfamide-induced hemorrhagic cystitis, and Zometa (zoledronic acid) for the treatment of patients with multiple myeloma and for patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. The recommended dose and schedule is 4 mg infused over 15 min every 3-4 wk. These three drugs represent three different types of drug approval: Gleevec is an accelerated approval and supplemental new drug application (NDA); Mesnex tablets represent an oral formulation of a drug approved 14 yr ago as an i.v. formulation, and Zometa represents a standard NDA for a noncytotoxic, supportive-care drug. Information provided includes rationale for drug development, study design, efficacy and safety results, and pertinent literature refs.
IT **220127-57-1**, Gleevec
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(imatinib mesylate, mesna tablets, and zoledronic acid approved by U.S. Food and Drug Administration)
RN 220127-57-1 HCAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



L4 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2

CRN 75-75-2
CMF C H4 O3 S

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:846494 HCAPLUS
DOCUMENT NUMBER: 139:82
TITLE: Cell cycle inhibitors and signal transduction inhibitors as antitumor agent for lung cancer
AUTHOR(S): Yamamoto, Nobuyuki; Ebisawa, Masako; Asai, Gyo; Takahashi, Toshiaki
CORPORATE SOURCE: Department of Respiratory Diseases, Shizuoka Prefectural Shizuoka Cancer Center, Japan
SOURCE: Bunshi Kokyukibyo (2002), 6(5), 393-401
CODEN: BUKOFC; ISSN: 1342-436X
PUBLISHER: Sentan Igakusha
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Japanese
AB A review. Cell cycle inhibitors such as cyclin dependent kinase inhibitors Flavopiridol and UCN-01 in their single dosage is not very effective in the treatment of lung cancer. Signal transduction inhibitors such as proteasome inhibitor PS-341 and tyrosine kinase inhibitor STI 571 in the treatment of lung cancer is reviewed with their mechanism.
IT **220127-57-1**, STI 571
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cell cycle inhibitors and signal transduction inhibitors)
RN 220127-57-1 HCAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

L4 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:720795 HCAPLUS
DOCUMENT NUMBER: 138:280580
TITLE: FDA new drug approvals in 2001
AUTHOR(S): Zhao, Kang; He, Lan; Reiner, John
CORPORATE SOURCE: The College of Pharmaceuticals and Biotechnology, Tianjin University, Peop. Rep. China
SOURCE: Frontiers of Biotechnology & Pharmaceuticals (2002), 3, 400-413
CODEN: FBPRBL
PUBLISHER: Science Press New York Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review covering the 24 new drugs approved by the Food and Drug Administration in the year 2001. Therapeutics are grouped according to the following coded areas: (A) agents affecting neurotransmitters and cytokines, (B) antiinflammatory agents, (C) hormone related agents, (D) anti-infectious agents, and (E) miscellaneous agents. A synopsis for each drug includes a brief description of its medical utility, a mechanism of action if known, a chemical structure, and a pathway for its synthesis.
IT **220127-57-1P**, Imatinib mesylate
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(FDA new drug approvals in 2001)
RN 220127-57-1 HCAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:167836 HCAPLUS
DOCUMENT NUMBER: 136:160790
TITLE: c-Kit inhibitor
AUTHOR(S): Nakajima, Motoo
CORPORATE SOURCE: Tsukuba Res. Lab., Novartis Pharma Inc., Japan
SOURCE: Byori to Rinsho (2002), 20(2), 205-210
CODEN: BYRIEM; ISSN: 0287-3745
PUBLISHER: Bunkodo
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Japanese

AB A review on the expression of Kit receptor in various tumors, history of the development of tyrosine kinase inhibitors, mutations in c-kit gene in gastrointestinal stromal tumor (GIST) and small cell lung carcinoma (SCLC), selectivity of tyrosine kinase inhibitors, and effects of STI571 in patients with GIST or SCLC.

IT 220127-57-1
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(STI 571; effect of Kit tyrosine kinase inhibitors in treatment of gastrointestinal stromal tumors)

RN 220127-57-1 HCAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

L4 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:647564 HCAPLUS
DOCUMENT NUMBER: 134:125648
TITLE: The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth
AUTHOR(S): Krystal, Geoffrey W.; Honsawek, Sittisak; Litz, Julie; Buchdunger, Elisabeth
CORPORATE SOURCE: Department of Medicine, Division of Hematology/Oncology and Department of Microbiology/Immunology McGuire, Virginia Commonwealth University, Richmond, VA, 23249, USA
SOURCE: Clinical Cancer Research (2000), 6(8), 3319-3326
CODEN: CCREF4; ISSN: 1078-0432
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB At least 70% of small cell lung cancers express the Kit receptor Tyr kinase and its ligand, stem cell factor (SCF). Numerous lines of evidence have demonstrated that this coexpression constitutes a functional autocrine loop, suggesting that inhibitors of Kit Tyr kinase activity could have therapeutic efficacy in this disease. STI571, formerly known as CGP 57148B, is a p.o. bioavailable 2-phenylaminopyrimide derivative that was designed as an Abl Tyr kinase inhibitor, but also has efficacy against the platelet-derived growth factor receptor and Kit in vitro. Pretreatment of the H526 small cell lung cancer (SCLC) cell line with STI571 inhibited SCF-mediated Kit activation with an IC50 of 0.1 μM as measured by inhibition of receptor Tyr phosphorylation and 0.2 μM as measured by immune complex kinase assay. Tis paralleled the inhibition of SCF-mediated growth by STI571, which had an IC50 of .apprx.0.3 μM. Growth inhibition in SCF-containing medium was accompanied by induction of apoptosis. STI571 efficiently blocked SCF-mediated activation of mitogen-activated protein kinase and Akt, but did not affect insulin-like growth factor-1 or serum-mediated mitogen-activated protein kinase or Akt activation. Growth of 5 of 6 SCLC cell lines in medium containing 10% FCS was inhibited by STI571 with an IC50 of .apprx.5 μM. Growth inhibition in serum-containing medium appeared to be cytostatic in nature because no increase in apoptosis was observed Despite this growth inhibition, STI571 failed to enhance the cytotoxicity of either carboplatinum or etoposide when coadministered. However, taken together with the minimal toxicity that this compound has shown in preclin. studies, these data suggest that STI571 could have a role in the treatment of SCLC, possibly to block or slow recurrence after chemotherapy-induced remissions.

IT 220127-57-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(STI 571; STI571 inhibited small cell lung cancer growth)

RN 220127-57-1 HCAPLUS

CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O

L4 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 75-75-2
CMF C H4 O3 S

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:578241 HCAPLUS
DOCUMENT NUMBER: 133:246891
TITLE: Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571
AUTHOR(S): Wang, Wen-Lan; Healy, Mary Ellen; Sattler, Martin; Verma, Shalini; Lin, Jeffrey; Maulik, Gautam; Stiles, Charles D.; Griffin, James D.; Johnson, Bruce E.; Salgia, Ravi
CORPORATE SOURCE: Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA
SOURCE: Oncogene (2000), 19(31), 3521-3528
CODEN: ONCNES; ISSN: 0950-9232
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Small cell lung cancer (SCLC) is an aggressive cancer characterized by several autocrine growth mechanisms including stem cell factor and its receptor c-Kit. In order to arrive at potentially new and novel therapy for SCLC, we have investigated the effects of the tyrosine kinase inhibitor, STI 571, on SCLC cell lines. It has been previously reported that STI 571 does not only inhibit cellular Abl tyrosine kinase activity but also the PDGF receptor and c-Kit tyrosine kinases at similar concns. (approx. 0.1 μM). There is no expression of the PDGF-receptor, and the Abl kinase is not activated by SCLC, but over 70% of SCLC contain the c-Kit receptor. Utilizing this preliminary data, we have determined that three (NCI-H69, NCI-H146 and NCI-H209) of five (including NCI-H82 and NCI-H249) SCLC cell lines had detectable c-Kit receptors and were inhibited in growth and viability at concns. 1-5 μM of STI 571 after 48 h of treatment. The SCLC cell lines, NCI-H69, NCI-H146 and NCI-H209, showed a dose-response (tested between 0.1-10 μM) inhibition of tyrosine phosphorylation of c-Kit as well as in vitro kinase activity (at 5 μM) of c-Kit in response to STI 571. STI 571 inhibited cell motility, as assessed by time-lapsed video microscopy, within 6 h of STI 571 treatment (5 μM). STI 571 also decreased intracellular levels of reactive oxygen species (ROS) by at least 60%, at a concentration (5 μM) that also inhibited cell growth. Cell cycle anal. of STI 571 responsive cells showed that cells were generally slowed in G2/M phase, but there was no arrest at G1/S. A downstream phosphorylation target of c-Kit, Akt, was not phosphorylated in response to stem cell factor in the presence of STI 571. These data imply that STI 571 inhibits growth of SCLC cells through a mechanism that involves inactivation of the tyrosine kinase c-Kit. The effectiveness of STI 571 in this study suggests this drug may be useful in a clin. trial, for patients with SCLC.

IT **220127-57-1**, STI 571
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by novel tyrosine kinase inhibitor STI 571)

RN 220127-57-1 HCAPLUS
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/ 519,654

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | | |
|---|---|---|---|
| NEWS | 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS | 2 | | "Ask CAS" for self-help around the clock |
| NEWS | 3 | DEC 21 | IPC search and display fields enhanced in CA/CAplus with the IPC reform |
| NEWS | 4 | DEC 23 | New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2 |
| NEWS | 5 | JAN 13 | IPC 8 searching in IFIPAT, IFIUDB, and IFICDB |
| NEWS | 6 | JAN 13 | New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC |
| NEWS | 7 | JAN 17 | Pre-1988 INPI data added to MARPAT |
| NEWS | 8 | JAN 17 | IPC 8 in the WPI family of databases including WPIFV |
| NEWS | 9 | JAN 30 | Saved answer limit increased |
| NEWS | 10 | JAN 31 | Monthly current-awareness alert (SDI) frequency added to TULSA |
| NEWS | 11 | FEB 21 | STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results |
| NEWS | 12 | FEB 22 | Status of current WO (PCT) information on STN |
| NEWS | 13 | FEB 22 | The IPC thesaurus added to additional patent databases on STN |
| NEWS | 14 | FEB 22 | Updates in EPFULL; IPC 8 enhancements added |
| NEWS | 15 | FEB 27 | New STN AnaVist pricing effective March 1, 2006 |
| NEWS | 16 | FEB 28 | MEDLINE/LMEDLINE reload improves functionality |
| NEWS | 17 | FEB 28 | TOXCENTER reloaded with enhancements |
| NEWS | 18 | FEB 28 | REGISTRY/ZREGISTRY enhanced with more experimental spectral property data |
| NEWS | 19 | MAR 01 | INSPEC reloaded and enhanced |
| NEWS | 20 | MAR 03 | Updates in PATDPA; addition of IPC 8 data without attributes |
| NEWS | 21 | MAR 08 | X.25 communication option no longer available after June 2006 |

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.



* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

10/ 519,654

FILE 'HOME' ENTERED AT 17:08:04 ON 16 MAR 2006

=> file reg
COST IN U.S. DOLLARS — SINCE FILE ENTRY: 0.21 — TOTAL SESSION: 0.21
FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 17:08:22 ON 16 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 MAR 2006 HIGHEST RN 877033-93-7
DICTIONARY FILE UPDATES: 15 MAR 2006 HIGHEST RN 877033-93-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

**********
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
**********

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s lometrexol
L1 2 LOMETREXOL

=> d scan l1

L1 2 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN L-Glutamic acid, N-[4-[2-[(6R)-2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]-, disodium salt (9CI)
MF C21 H25 N5 O6 . 2 Na

Absolute stereochemistry.

10/ 519,654



●2 Na

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s imatinib
L2 2 IMATINIB

=> d scan l2

L2 2 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI)
MF C29 H31 N7 O
CI COM



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> d his

(FILE 'HOME' ENTERED AT 17:08:04 ON 16 MAR 2006)

FILE 'REGISTRY' ENTERED AT 17:08:22 ON 16 MAR 2006
L1 2 S LOMETREXOL
L2 2 S IMATINIB

=> log y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 9.96 | 10.17 |

STN INTERNATIONAL LOGOFF AT 17:09:05 ON 16 MAR 2006